Focal liver lesions: Detection and characterization at double-contrast liver MR imaging with ferucarbotran and gadobutrol versus single-contrast liver MR imaging

Radiology

Volumn 253, Issue 3, 2009, Pages 724-733

  Heilmaier, Christina ^a,b   Lutz, Amelie M ^a,c   Bolog, Nicolae ^a   Weishaupt, Dominik ^a,d   Seifert, Burkhardt ^e   Willmann, Jürgen K ^a,c  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY HOSPITAL ESSEN   (Germany)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d TRIEMLI HOSPITAL   (Switzerland)

^e UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

FERUCARBOTRAN; GADOBUTROL; CONTRAST MEDIUM; DIAGNOSTIC AGENT; MAGNETITE; ORGANOMETALLIC COMPOUND; SUPERPARAMAGNETIC IRON OXIDE;

ADULT; AGED; ARTICLE; BENIGN TUMOR; CANCER DIAGNOSIS; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DISEASE COURSE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; LIVER CELL CARCINOMA; LIVER INJURY; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; UNSPECIFIED SIDE EFFECT; COMPARATIVE STUDY; COMPUTER ASSISTED DIAGNOSIS; DIFFERENTIAL DIAGNOSIS; LIVER TUMOR; METHODOLOGY; MIDDLE AGED; NONPARAMETRIC TEST; RECEIVER OPERATING CHARACTERISTIC;

ADULT; AGED; CARCINOMA, HEPATOCELLULAR; CONTRAST MEDIA; DIAGNOSIS, DIFFERENTIAL; FEMALE; FERROSOFERRIC OXIDE; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; ORGANOMETALLIC COMPOUNDS; RETROSPECTIVE STUDIES; ROC CURVE; STATISTICS, NONPARAMETRIC;

EID: 73949156880     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.2533090161     Document Type: Article

References (35)

1. Elsayes KM, Narra VR, Yin Y, Mukundan G, Lammle M, Brown JJ. Focal hepatic lesions: diagnostic value of enhancement pattern approach with contrast-enhanced 3D gradient-echo MR imaging. RadioGraphics 2005;25:1299-1320.
2. Semelka RC, Martin DR, Balci C, Lance T. Focal liver lesions: comparison of dual-phase CT and multisequence multiplanar MR imaging including dynamic gadolinium enhancement. J Magn Reson Imaging 2001;13:397-401.
3. Lutz AM, Willmann JK, Goepfert K, Marincek B, Weishaupt D. Hepatocellular carcinoma in cirrhosis: enhancement patterns at dynamic gadoliniumand superparamagnetic iron oxide-enhanced T1-weighted MR imaging. Radiology 2005;237:520-528.
4. Oudkerk M, Torres CG, Song B, et al. Characterization of liver lesions with mangafodipir trisodium-enhanced MR imaging: multicenter study comparing MR and dual-phase spiral CT. Radiology 2002;223:517-524.
5. Reimer P, Jahnke N, Fiebich M, et al. Hepatic lesion detection and characterization: value of nonenhanced MR imaging, superparamagnetic iron oxide-enhanced MR imaging, and spiral CT-ROC analysis. Radiology 2000;217:152-158.
6. Vogl TJ, Schwarz W, Blume S, et al. Preoperative evaluation of malignant liver tumors: comparison of unenhanced and SPIO (Resovist)-enhanced MR imaging with biphasic CTAP and intraoperative US. Eur Radiol 2003;13:262-272.
7. Reimer P, Balzer T. Ferucarbotran (Resovist): a new clinically approved RES-specific contrast agent for contrast-enhanced MRI of the liver-properties, clinical development, and applications. Eur Radiol 2003;13:1266-1276.
8. Simon G, Link TM, Wortler K, et al. Detection of hepatocellular carcinoma: comparison of Gd-DTPA- and ferumoxides-enhanced MR imaging. Eur Radiol 2005;15:895-903.
9. Ward J, Guthrie JA, Scott DJ, et al. Hepato-cellular carcinoma in the cirrhotic liver: double-contrast MR imaging for diagnosis. Radiology 2000;216:154-162.
10. Bhartia B, Ward J, Guthrie JA, Robinson PJ. Hepatocellular carcinoma in cirrhotic livers: double-contrast thin-section MR imaging with pathologic correlation of explanted tissue. AJR Am J Roentgenol 2003;180:577-584.
11. Cheng WZ, Zeng MS, Yan FH, et al. Ferucarbotran versus Gd-DTPA-enhanced MR imaging in the detection of focal hepatic lesions. World J Gastroenterol 2007;13:4891-4896.
12. Kang BK, Lim JH, Kim SH, et al. Preoperative depiction of hepatocellular carcinoma: ferumoxides-enhanced MR imaging versus triple-phase helical CT. Radiology 2003;226:79-85.
13. Kim MJ, Kim JH, Chung JJ, Park MS, Lim JS, Oh YT. Focal hepatic lesions: detection and characterization with combination gadolinium-and superparamagnetic iron oxide-enhanced MR imaging. Radiology 2003;228:719-726.
14. Kim MJ, Kim JH, Lim JS, et al. Detection and characterization of focal hepatic lesions: mangafodipir vs. superparamagnetic iron oxide-enhanced magnetic resonance imaging. J Magn Reson Imaging 2004;20:612-621.
15. Kim SH, Choi D, Lim JH, et al. Ferucarbotran-enhanced MRI versus triple-phase MDCT for the preoperative detection of hepatocellular carcinoma. AJR Am J Roentgenol 2005;184:1069-1076.
16. Ba-Ssalamah A, Heinz-Peer G, Schima W, et al. Detection of focal hepatic lesions: comparison of unenhanced and SHU 555 A-enhanced MR imaging versus biphasic helical CTAP. J Magn Reson Imaging 2000;11:665-672.
17. Nakamura H, Ito N, Kotake F, Mizokami Y, Matsuoka T. Tumor-detecting capacity and clinical usefulness of SPIO-MRI in patients with hepatocellular carcinoma. J Gastroenterol 2000;35:849-855.
18. Pauleit D, Textor J, Bachmann R, et al. Hepatocellular carcinoma: detection with gadolinium-and ferumoxides-enhanced MR imaging of the liver. Radiology 2002;222:73-80.
19. Savranoglu P, Obuz F, Karasu S, et al. The role of SPIO-enhanced MRI in the detection of malignant liver lesions. Clin Imaging 2006;30:377-381.
20. Guiu B, Loffroy R, Ben Salem D, et al. Combined SPIO-gadolinium magnetic resonance imaging in cirrhotic patients: negative predictive value and role in screening for hepatocellular carcinoma. Abdom Imaging 2008;33:520-528.
21. Guiu B, Loffroy R, Cercueil JP. Double-contrast MRI in patients with cirrhosis. AJR Am J Roentgenol 2008;191:W78.
22. Hanna RF, Kased N, Kwan SW, et al. Doublecontrast MRI for accurate staging of hepatocellular carcinoma in patients with cirrhosis. AJR Am J Roentgenol 2008;190:47-57.
23. Kwak HS, Lee JM, Kim CS. Preoperative detection of hepatocellular carcinoma: comparison of combined contrast-enhanced MR imaging and combined CT during arterial portography and CT hepatic arteriography. Eur Radiol 2004;14:447-457.
24. Yoo HJ, Lee JM, Lee MW, et al. Hepatocellular carcinoma in cirrhotic liver: double-contrast-enhanced, high-resolution 3.0T-MR imaging with pathologic correlation. Invest Radiol 2008;43:538-546.
25. Hanna RF, Aguirre DA, Kased N, Emery SC, Peterson MR, Sirlin CB. Cirrhosis-associated hepatocellular nodules: correlation of histopathologic and MR imaging features. Radio-Graphics 2008;28:747-769.
26. Bolog N, Pfammatter T, Mullhaupt B, Andreisek G, Weishaupt D. Double-contrast magnetic resonance imaging of hepatocellular carcinoma after transarterial chemoembolization. Abdom Imaging 2008;33:313-323.
27. Zech CJ, Seiderer J, Reinisch W, et al. Thioguanin-induced nodular regenerative hyperplasia of the liver: ROC analysis of different MR techniques. Eur Radiol 2007;17:1898-1905.
28. Kanematsu M, Semelka RC, Matsuo M, et al. Gadolinium-enhanced MR imaging of the liver: optimizing imaging delay for hepatic arterial and portal venous phases - a prospective randomized study in patients with chronic liver damage. Radiology 2002;225:407-415.
29. Landis JR, Koch GG. An application of hierarchical kappa-type statistics in the assessment of majority agreement among multiple observers. Biometrics 1977;33:363-374.
30. Hamm B, Staks T, Taupitz M, et al. Contrast-enhanced MR imaging of liver and spleen: first experience in humans with a new superparamagnetic iron oxide. J Magn Reson Imaging 1994;4:659-668.
31. Gandhi SN, Brown MA, Wong JG, Aguirre DA, Sirlin CB. MR contrast agents for liver imaging: what, when, how. RadioGraphics 2006;26:1621-1636.
32. Kim YK, Kwak HS, Han YM, Kim CS. Usefulness of combining sequentially acquired gadobenate dimeglumine-enhanced magnetic resonance imaging and resovist-enhanced magnetic resonance imaging for the detection of hepatocellular carcinoma: comparison with computed tomography hepatic arteriography and computed tomography arterioportography using 16-slice multidetector computed tomography. J Comput Assist Tomogr 2007;31:702-711.
33. Paley MR, Mergo PJ, Torres GM, Ros PR. Characterization of focal hepatic lesions with ferumoxides-enhanced T2-weighted MR imaging. AJR Am J Roentgenol 2000;175:159 -163.
34. Qayyum A, Thoeni RF, Coakley FV, Lu Y, Guay JP, Ferrell LD. Detection of hepatocellular carcinoma by ferumoxides-enhanced MR imaging in cirrhosis: incremental value of dynamic gadolinium-enhancement. J Magn Reson Imaging 2006;23:17-22.
35. Grazioli L, Morana G, Kirchin MA, Schneider G. Accurate differentiation of focal nodular hyperplasia from hepatic adenoma at gadobenate dimeglumine-enhanced MR imaging: prospective study. Radiology 2005;236:166-177.